Silexion Therapeutics (SLXN) Liabilities and Shareholders Equity (2023 - 2026)

Silexion Therapeutics' Liabilities and Shareholders Equity history runs 4 years deep, the most recent figure standing at $4.6 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 44.61% year-over-year to $4.6 million; the TTM figure through Mar 2026 stood at $29.2 million (up 76.36% YoY), while the FY2025 annual figure was $7.2 million, up 152.01% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $4.6 million, down from $7.2 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $11.6 million in Q3 2025, with the low at $2.3 million in Q2 2024.
• The 4-year median for Liabilities and Shareholders Equity is $4.9 million (2023), against an average of $5.5 million.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity plunged 45.53% in 2024, then soared 276.22% in 2025.
• Silexion Therapeutics' Liabilities and Shareholders Equity stood at $5.3 million in 2023, then plunged by 45.53% to $2.9 million in 2024, then soared by 152.01% to $7.2 million in 2025, then plunged by 36.22% to $4.6 million in 2026.
• Business Quant data shows SLXN's Liabilities and Shareholders Equity at $4.6 million in Q1 2026, $7.2 million in Q4 2025, and $11.6 million in Q3 2025.